Growth Hormone Releasing Peptide-2 (GHRP-2), also known as Pralmorelin, is a synthetic peptide that acts as a growth hormone secretagogue, meaning it stimulates the body’s natural production of growth hormone (GH). GHRP-2 functions as an agonist of ghrelin, a gut-derived peptide often referred to as the “hunger hormone,” which binds to the growth hormone secretagogue receptor (GHS-R). Ghrelin plays a key role in stimulating growth hormone secretion and initiating appetite.
Uses of GHRP-2
GHRP-2 is primarily used to promote muscle growth, reduce body fat, and improve flexibility and joint health. It has also been shown to enhance recovery from injuries and physical training. Additionally, GHRP-2 has positive effects on sleep, anti-aging benefits, and overall health and wellness. Increased growth hormone levels triggered by GHRP-2 lead to greater production of IGF-1, a protein that supports lean body mass, muscle growth, and fat reduction.
Long-term use of GHRP-2 can significantly improve strength, endurance, and athletic performance. The peptide is also recognized for its potential to combat age-related decline, helping to maintain physical capacity and vitality over time.
One of the key advantages of GHRP-2 over other growth hormone releasing peptides is its ability to stimulate growth hormone production without inducing the intense hunger side effects commonly associated with GHRP-6. This makes it especially effective for improving lean body composition and boosting physical performance while avoiding unwanted weight gain.
Mechanism of Action
GHRP-2 enhances natural growth hormone production through two primary mechanisms:
- Amplifying Growth Hormone Release: GHRP-2 intensifies the natural signal for growth hormone release, leading to a substantial increase in the secretion of growth hormone.
- Inhibiting Somatostatin: GHRP-2 suppresses the activity ofsomatostatin, a hormone that normally inhibits growth hormone production. By blocking somatostatin, GHRP-2 ensures that the body produces more growth hormone.
Additionally, GHRP-2 activates ghrelin, the peptide hormone produced in the gastrointestinal system. Ghrelin’s effects on growth hormone secretion are well-documented, and its activation by GHRP-2 plays a significant role in stimulating growth hormone production.
Importantly, GHRP-2 stimulates the body’s natural growth hormone production in a way that mimics the body’s natural release patterns. Unlike synthetic hGH (human growth hormone), which can cause the shutdown of natural growth hormone production, GHRP-2 does not result in this negative feedback. This means that GHRP-2 supports natural growth hormone secretion without disrupting the body’s ability to produce growth hormone on its own.
In summary, GHRP-2 is a powerful growth hormone secretagogue with significant benefits for muscle growth, fat loss, recovery, and overall well-being. Its ability to enhance natural growth hormone production while minimizing side effects such as hunger and hormone suppression makes it one of the most effective peptides for athletic performance and anti-aging purposes.
References
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537–1545.CrossrefPubMedGoogle Scholar
- Corneli G, Gasco V, Prodam F, Grottoli S, Aimaretti G, Ghigo E. Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood.Pituitary. 2007;10(2):141–149.
- Muccioli G, Broglio F, Valetto MR, et al. Growth hormone-releasing peptides and the cardiovascular system.Ann Endocrinol (Paris). 2000;61(1):27–31.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.Br J Pharmacol. 2014;171(8):2029–2050.
- Broglio F, Fubini A, Morello M, et al. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy.Clin Endocrinol (Oxf). 1999;50(4):417–430.
- Bowers CY. Growth hormone-releasing peptide (GHRP).Cell Mol Life Sci. 1998;54(12):1316–1329.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach.Nature. 1999;402(6762):656–660.
- Bhattacharya SK, Andrews K, Beveridge R, et al. Discovery of PF-5190457, a potent, selective, and orally bioavailable ghrelin receptor inverse agonist clinical candidate.ACS Med Chem Lett. 2014;5(5):474–479.
- Khatib MN, Simkhada P, Gode D. Cardioprotective effects of ghrelin in heart failure: from gut to heart.Heart Views. 2014;15(3):74–76.
- Kishimoto I, Tokudome T, Hosoda H, Miyazato M, Kangawa K. Ghrelin and cardiovascular diseases.J Cardiol. 2012;59(1):8–13.
- Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile.J Cachexia Sarcopenia Muscle. 2014;5(4):329–337.
- Root AW, Root MJ. Clinical pharmacology of human growth hormone and its secretagogues.Curr Drug Targets Immune Endocr Metabol Disord. 2002;2(1):27–52.
- Broglio F, Arvat E, Gottero C, et al. Natural and synthetic growth hormone secretagogues: do they have therapeutic potential?Treat Endocrinol. 2003;2(3):153–163.
- Selman-Housein-Bernal KH, Hernández-Bernal F, Abreu-Cruz AA, Valenzuela-Silva C, Berlanga-Acosta J, López-Saura PA. Seguridad clínica del péptido liberador de la hormona de crecimiento-6 (GHRP-6) en voluntarios sanos.Investigaciones Médico Quirúrgicas. 2014;6(1):81–91.
- Valiente-Mustelier J, Garcia del Barco D, Guillen-Nieto G, et al. Cardiotropic effect of GHRP-6: in vivo characterization by echocardiography.Biotecnología Aplicada. 2013;30:285–289.
- Marleau S, Mulumba M, Lamontagne D, Ong H. Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies.Cardiovasc Res. 2006;69(1):26–35.
